A recent survey of twenty-five brokerage analysts shows seventy-six percent assigning McKesson a Buy or Strong Buy rating, up from sixty-eight percent three months earlier. The consensus target for next twelve-month total return implies a twelve-percent upside, reflecting growing confidence in the company’s ability to capture higher-margin specialty drug distribution opportunities. Several firms noted McKesson’s investments in automated dispensing technology and expanded oncology logistics as key drivers behind the upgrades.

For the quarter ended December 31, 2025, McKesson reported earnings per share of $9.34, a 16.3% increase from $8.03 a year ago, and topping the consensus estimate of $9.31. Revenue climbed approximately 8% year-over-year, led by specialty pharmaceuticals and oncology segment growth. Gross profit margin expanded by 50 basis points as the company realized greater pricing leverage in higher-value product lines, while operating expenses remained flat as a percentage of sales due to ongoing efficiency initiatives.

McKesson raised its fiscal 2026 adjusted EPS guidance by $0.20 to a range of $32.40–$32.80, driven by stronger-than-expected volumes in cancer and rare-disease therapies. Management now forecasts specialty distribution revenue growth of 18% for the year, up from the prior outlook of 15–17%, and anticipates free cash flow exceeding $3.5 billion. The company reiterated plans to return at least $2.5 billion to shareholders through dividends and share repurchases, underscoring its commitment to capital allocation discipline.